Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 4/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055935 | 0.98 | TSHR (0.48) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL15055600 | 0.98 | TSHR (0.48) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL250369 | 0.96 | CYP2C19 (0.52) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL249838 | 0.94 | CYP2C19 (0.55) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL248594 | 0.94 | CYP2C19 (0.55) | CYP2C19LMNATSHRNFKB1PMP22 | |
| Adipic Acid SCHEMBL2227837 | 0.94 | CYP2C19 (0.50) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL251145 | 0.94 | CYP2C19 (0.55) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL9437316 | 0.94 | CYP2C19 (0.50) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL250844 | 0.94 | CYP2C19 (0.55) | CYP2C19LMNATSHRNFKB1PMP22 | |
| SCHEMBL249976 | 0.94 | CYP2C19 (0.50) | CYP2C19LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4438443-A | Method of recording information on a medium in the form of electrical signals | INSTITUT RADIOTEKHNIKI I ELEKTRONIKI AKADEMII NAUK SSSR (SU) | 1984-03-20 | — | — | US | claimed |
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4522595-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | The Scripps Research Institute (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220559-A2 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-16 | — | — | WO | disclosed |
| US-5859239-A | Mercaptoalkanoylamino and acylmercaptoalkanoylamino benzoxazepines and benzothiazepines | E. R. SQUIBB & SONS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5856476-A | Processes for preparing azepiones useful as intermediates in the preparation of inhibitors of angiotensin converting enzyme and neutral endopeptidase | E. R. SQUIBBS & SONS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856477-A | HYPOTENSIVE AGENTS; CONGESTIVE HEART FAILURE | E. R. SQUIBB & SONS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5723602-A | ANGIOTENSIN CONVERTING ENZYME AND ENDOPEPTIDASE INHIBITORS, CARDIOVASCULAR DISORDERS | E. R. SQUIBB & SONS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5723457-A | COMPOUMDS FOR CARDIOVASCULAR DISORDERS AND INHIBITORS OF ANGIOTENSIN CONVERTING ENZYMES | E. R. SQUIBB & SONS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5646276-A | ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-4438443-A | Method of recording information on a medium in the form of electrical signals | INSTITUT RADIOTEKHNIKI I ELEKTRONIKI AKADEMII NAUK SSSR (SU) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326731-A1 | CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS | DNPH1, NISCH, PTMA | CYP2C19 2563/4885LMNA 173/4885TSHR 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.